Literature DB >> 17406388

Selection and characterization of large collections of peptide aptamers through optimized yeast two-hybrid procedures.

Marc B T Bickle1, Eric Dusserre, Olivier Moncorgé, Hélène Bottin, Pierre Colas.   

Abstract

Peptide aptamers are combinatorial proteins that specifically bind intracellular proteins and modulate their function. They are powerful tools to study protein function within complex regulatory networks and to guide small-molecule drug discovery. Here we describe methodological improvements that enhance the yeast two-hybrid selection and characterization of large collections of peptide aptamers. We provide a detailed protocol to perform high-efficiency transformation of peptide aptamer libraries, in-depth validation experiments of the bait proteins, high-efficiency mating to screen large numbers of peptide aptamers and streamlined confirmation of the positive clones. We also describe yeast two-hybrid mating assays, which can be used to determine the specificity of the selected aptamers, map their binding sites on target proteins and provide structural insights on their target-binding surface. Overall, 12 weeks are required to perform the protocols. The improvements on the yeast two-hybrid method can be also usefully applied to the screening of cDNA libraries to identify protein interactions.

Mesh:

Substances:

Year:  2006        PMID: 17406388     DOI: 10.1038/nprot.2006.32

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  19 in total

Review 1.  Tools used to study how protein complexes are assembled in signaling cascades.

Authors:  Susan Dwane; Patrick A Kiely
Journal:  Bioeng Bugs       Date:  2011-09-01

2.  Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth.

Authors:  Astrid Weiss; Boris Brill; Corina Borghouts; Natalia Delis; Laura Mack; Bernd Groner
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

Review 3.  Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.

Authors:  Bernd Groner; Axel Weber; Laura Mack
Journal:  Bioengineered       Date:  2012-07-24       Impact factor: 3.269

4.  A Quantitative Tri-fluorescent Yeast Two-hybrid System: From Flow Cytometry to In cellula Affinities.

Authors:  David Cluet; Ikram Amri; Blandine Vergier; Jérémie Léault; Astrid Audibert; Clémence Grosjean; Dylan Calabrési; Martin Spichty
Journal:  Mol Cell Proteomics       Date:  2020-02-03       Impact factor: 5.911

Review 5.  Peptide aptamers: development and applications.

Authors:  Sergey Reverdatto; David S Burz; Alexander Shekhtman
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

6.  CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.

Authors:  Vincent J Guen; Carly Gamble; Marc Flajolet; Sheila Unger; Aurélie Thollet; Yoan Ferandin; Andrea Superti-Furga; Pascale A Cohen; Laurent Meijer; Pierre Colas
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 7.  In-Cell NMR Spectroscopy of Intrinsically Disordered Proteins.

Authors:  Nicholas Sciolino; David S Burz; Alexander Shekhtman
Journal:  Proteomics       Date:  2019-01-15       Impact factor: 3.984

Review 8.  Peptide aptamers: tools to negatively or positively modulate HSPB1(27) function.

Authors:  Benjamin Gibert; Stéphanie Simon; Valeriya Dimitrova; Chantal Diaz-Latoud; André-Patrick Arrigo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-03-25       Impact factor: 6.237

9.  Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models.

Authors:  Joshua A Kritzer; Shusei Hamamichi; J Michael McCaffery; Sandro Santagata; Todd A Naumann; Kim A Caldwell; Guy A Caldwell; Susan Lindquist
Journal:  Nat Chem Biol       Date:  2009-07-13       Impact factor: 15.040

Review 10.  The eleven-year switch of peptide aptamers.

Authors:  Pierre Colas
Journal:  J Biol       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.